Interpreting clinical trial results is not for the faint of heart. But STAT covers the clinical trials landscape with great precision. From data on Eli Lilly’s Alzheimer’s drug donanemab to the readout on Sage’s depression drug zuranolone, there is an art to reading, and writing, scientific results — and we’re here to help you learn it.
If you upgrade to a STAT+ account today, you’ll get instant access to STAT’s guide to interpreting clinical trials and unlock our subscriber-only stories and newsletters.
SUBSCRIBE NOW
You’ll also be joining thousands of key decision-makers and companies in the life sciences who seek trusted and tough-minded coverage of biotech, pharma, health tech, science, and public health.
A STAT+ subscription includes access to all subscriber-only stories and archives of our award-winning journalism, subscriber-only newsletters, discounts on exclusive events (virtual and in-person) across the country, and access to premium data tools.
Free with your STAT+ subscription, the guide to interpreting clinical trials report includes a definition of spin in clinical trials, supported by real life examples; four key questions to ask when evaluating results; an overview of additional tools you need to read results more critically; and analysis of the red flags you should look for in clinical trial design, execution, and reporting of results.
There's limited time to sign up at these current rates.
In the meantime, we'll continue to deliver you trusted, and authoritative, journalism every day in 2022. Thank you for being part of the STAT community.
SUBSCRIBE NOW
No comments